These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 1756252)

  • 21. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E; Scharrer I
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S; Lusher JM; Abildgaard CF; Kasper CK; Allred R; Hurst D
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
    Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
    Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
    Konkle BA; Stasyshyn O; Chowdary P; Bevan DH; Mant T; Shima M; Engl W; Dyck-Jones J; Fuerlinger M; Patrone L; Ewenstein B; Abbuehl B
    Blood; 2015 Aug; 126(9):1078-85. PubMed ID: 26157075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.
    Coyle TE; Reding MT; Lin JC; Michaels LA; Shah A; Powell J
    J Thromb Haemost; 2014 Apr; 12(4):488-96. PubMed ID: 24843882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
    Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
    Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Arkin S; Rose E; Forster A; Aledort LM
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):47-51. PubMed ID: 1908129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transgenic pigs produce functional human factor VIII in milk.
    Paleyanda RK; Velander WH; Lee TK; Scandella DH; Gwazdauskas FC; Knight JW; Hoyer LW; Drohan WN; Lubon H
    Nat Biotechnol; 1997 Oct; 15(10):971-5. PubMed ID: 9335047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.